Background: Pancreaticoduodenectomies are often undertaken with suspicion of malignancy. We
Radiographical identification of a pancreatic mass in a symptomatic patient is often the start of a diagnostic dilemma, which surgeons are facing with increasing frequency given the almost ubiquitous use of computed tomography (CT) in today's healthcare system. Pancreatectomies are often undertaken without histological confirmation of cancer as definitive diagnoses are difficult to obtain, and not without risk. Furthermore, a biopsy of the pancreatic mass is not a prerequisite to operative exploration in current care algorithms 1 given the likelihood of malignancy. In an analysis of nearly 2000 pancreaticoduodenectomies, 78%
of asymptomatic pancreatic masses resected harboured premalignant and/or malignant disease whereas 76% of symptomatic masses harboured malignant disease. 2 For the subset of patients with pancreatic adenocarcinoma, survival was significantly improved for those undergoing resection of cancers before the onset of symptoms. 2 In another study of 212 patients with cystic pancreatic lesions seen at a single tertiary care centre, almost 60% had malignant and/or premalignant disease, including over half of the patients seen with a history of pancreatitis. 3 Clearly timely intervention is important for patients with radiographical demonstration of a pancreatic mass. However, broad application of pancreaticoduodenectomy for suspicions of malignancy will result in a number of patients undergoing unnecessary resections, with attendant risks, for non-malignant or non-premalignant disease. On the contrary, observation with serial imaging or bypass procedures for those without definitive diagnoses of cancer will undoubtedly lead to delays in diagnosis of malignancy with advances in stage, suboptimal treatments and, ultimately, shorter survival. We undertook this study to better define those patients undergoing unnecessary pancreaticoduodenectomies, which we define arbitrarily for the purposes of this study, irrespective of any associated symptoms, as those resections undertaken for suspicion of malignancy that, after final pathological examination, were without malignant or premalignant disease. Specifically, we sought to gain insight as to how and why surgeons are misled. Our hypotheses in undertaking this study were that unnecessary pancreaticoduodenectomies are infrequent, the majority of patients undergoing unnecessary pancreaticoduodenectomies could be identified preoperatively and surgeons would most commonly be led astray by misinterpretation of radiographic imaging.
Methods
With institutional review board approval, data were extracted from a prospectively maintained database on all patients undergoing pancreaticoduodenectomy at our institution. Indications and preoperative diagnoses for patients undergoing pancreaticoduodenectomy were determined. Patients undergoing pancreaticoduodenectomy for malignancy or suspicion of malignancy were identified and categorized into two groups based upon final review by Pathology: patients with disease necessitating pancreaticoduodenectomy (i.e. necessary pancreaticoduodenectomy) or patients with disease not necessitating pancreaticoduodenectomy (i.e. unnecessary pancreaticoduodenectomy). Final diagnoses of patients undergoing necessary pancreaticoduodenectomies are listed in Table 1 . Patients undergoing unnecessary pancreaticoduodenectomies were considered to have done so irrespective of symptoms or the potential need for operative intervention (e.g. bypass or pancreaticoduodenctomy) as a result of those symptoms.
The clinical histories, including past medical history as well as the circumstances prompting presentation, and all pertinent imaging data were reviewed for patients undergoing unnecessary pancreaticoduodenctomy. These data were reviewed independently by at least two surgeons, at least one of whom was not involved in the care of the individual patient in question.
Data were analysed utilizing Graphpad Prism 5.0 and Graphpad Instat 3.0 (Graphpad Software, San Diego, CA). Comparisons were undertaken utilizing the Mann-Whitney U-test. Data are presented as median, mean Ϯ standard deviation, where appropriate. Significance was accepted with 95% probability.
Results
From 1996 to 2007, 551 patients underwent pancreaticoduodenectomies at our institution. Of these patients, 17 (3%) underwent pancreaticoduodenectomy for symptomatic relief from known chronic pancreatitis and were thus excluded from further analysis. Malignant disease was identified on final examination by Pathology in 411 patients and premalignant tumours were identified in 65 patients (Table 1) . These patients were considered to have undergone pancreaticoduodenectomy out of necessity and were not analysed further.
Non-neoplastic diseases or neoplastic disease of extremely low malignant potential were identified upon final examination by Pathology in 58 (11%) patients. Of note, two patients did not have sufficient data for evaluation and were thus excluded from our final analysis. The median age for patients undergoing pancreaticoduodenectomy unnecessarily based upon final examination by Pathology was 58 years, 59 Ϯ 12.1. Presenting symptoms included pain (61%), jaundice (48%) and weight loss (41%), and were noted for a median duration of 1.0 month, 5 Ϯ 11.9 prior to pancreaticoduodenectomy. All patients undergoing pancreaticoduodenectomy underwent triphasic CT scans utilizing thin cuts through the pancreas; 36 (64%) had solid masses and 14 (25%) had cystic masses on CT scans (Table 2 ). Tumour size was 4.1 cm, 4.1 Ϯ 1.31 for patients presenting with solid masses and 2.3 cm, 2.1 Ϯ 1.0 for patients presenting with cystic masses. Multiple symptoms at presentation were noted in 64% of patients, and 18% presented with a single symptom. Out of 56 patients undergoing pancreaticoduodenectomy for the presumptive diagnosis of malignancy, 36 (64%) had pancreatitis noted on Ampullary adenocarcinoma (65) Cholangiocarcinoma (49) Duodenal adenocarcinoma (14) Pancreatobiliary carcinoma (12) Islet cell carcinoma (9) Lymphoma (5) GI Stromal tumour (3) Liposarcoma (1) Squamous cell carcinoma (1) Premalignant disease: 65
Neuroendocrine tumour (18) Mucinous cystadenoma (14) Ampullary adenoma (6) Choledocal cyst (3)
Serous cystadenoma >4 cm (5) Patient total: 493 examination by Pathology. The final diagnoses per Pathology for patients undergoing pancreaticoduodenectomy unnecessarily are depicted in Table 3 . Careful review of all data for patients undergoing pancreaticoduodenectomies without premalignant/neoplastic disease or malignant disease led to the identification of specific inadequacies in management or misleading information in the care of these patients. Patients were then codified along the specific failures in evaluation and/or management.
Patients with final diagnoses of pancreatitis that could have and should have been identified preoperatively with available data Eleven patients had sufficient clinical histories and imaging characteristics to have yielded a very high suspicion for pancreatitis (Table 2) . Six (55%) of these patients had a history of chronic pancreatitis, two of whom presented with cystic masses on CT, which proved to be pseudocysts on final examination by Pathology. Five patients had recent episodes of acute pancreatitis or recent onset of known precipitating events such as choledocholithiasis. In addition, of the eight patients presenting with a solid mass, seven had distinct evidence of peripancreatic inflammation most consistent with pancreatitis. The average duration of symptoms prior to operative intervention for these 11 patients was 10 months, 16.4 Ϯ 19.5, which was longer than the symptom duration experienced by other patients undergoing necessary or unnecessary pancreaticoduodenectomies (P = 0.01, unpaired Student's t-test).
Patients with false-positive preoperative biopsies Ten patients were referred for pancreaticoduodenectomy with biopsies documenting adenocarcinoma; each was a false-positive biopsy based on examination by Pathology of the resected specimens. Of note, seven of these patients had biopsies outside our facility and were not reviewed within our own institution. Five of these patients had false-positive fine needle aspirations (FNAs) via endoscopic ultrasound (EUS); four patients had false-positive brushings via endoscopic retrograde cholangiopancreatography (ERCP). One false-positive biopsy was obtained during celiotomy, pancreatic biopsy, limited resection of the pancreatic head and lateral pancreaticojejunostomy for chronic pancreatitis. This biopsy was reviewed, and the presence of cancer was confirmed by numerous pathologists across the United States prior to reoperation and pancreaticoduodenectomy.
Patients with misinterpretations of imaging
Misinterpretations of imaging occurred in six (11%) patients, four of whom had cystic masses on CT (Table 2 ); in each of these four patients the diagnosis by Pathology was a serous cystadenoma less than 4 cm in size ( Table 3 ). The imaging of each serous cystadenoma was misinterpreted despite characteristic imaging appearances. Two patients presented with pancreatic head fullness with abdominal pain and nausea. These two patients had no definable pathology in their specimen and persistence of symptoms after the procedure. Notably, half of the patients were asymptomatic ( Table 2) .
Patients requiring further workup
Four patients were identified for whom further workup would have likely led to the correct diagnosis preoperatively. None of these four patients were asymptomatic. Preoperative evaluation and symptoms surrounding presentation are depicted in Table 2 . Two patients presented with a solid mass on computed tomography (CT) and were ultimately found to have chronic pancreatitis. Surgeons felt that a preoperative ERCP or intra-operative ultrasound would have yielded the correct diagnosis. These two patients had pancreatitis associated with pancreatic duct stones (1) and choledocholithiasis (1). Two additional patients had intramuscular duodenal inclusion cysts, which surgeons felt could have been delineated with the use of intra-operative ultrasonography.
Patients with misleading clinical and/or imaging indications for pancreaticoduodenectomy
After careful review, 26 patients could not have been identified as having non-neoplastic pathology or neoplastic pathology not requiring pancreaticoduodenectomy (e.g. small serous cyst) based upon evaluation of preoperative data. In other words, surgeons felt as though these 26 patients would have again warranted pancreaticoduodenectomy. All but four (15%) of these patients were symptomatic at presentation and 72% experienced pain, 60% experienced jaundice and 56% experienced weight loss (Table 2) . Twenty (80%) of these patients presented with a solid mass on CT scan, 15 of whom were ultimately diagnosed with pancreatitis despite lack of corroborating history and precipitating events (no antecedent history of gallstone disease, alcoholism, recent ERCP, etc). Five additional patients presented with a solid mass on CT and ultimately had rare diagnoses such as intrapancreatic biliary hamartoma (1), intrapancreatic caseating granulomas (1) or no definable pathology (3) ( Table 3) . Four patients presented with biliary strictures causing obstructive jaundice. Each of these four patients underwent ERCP with brushings, and each cytological evaluation demonstrated atypical cells. Pancreatitis was the final pathological diagnosis in each of these four patients. One patient presented with a cystic mass and abdominal pain, nausea and fatigue. This patient ultimately proved to have a serous cystadenoma on final examination by Pathology despite an atypical appearance on CT and magnetic resonance (MR) scans.
Discussion
The decision to operate upon patients without confirmation of cancer potentially places patients at risk for all the complications associated with an operation without its advantages (e.g. improved survival). This is particularly true for patients with presumed pancreatic cancers, given the morbidity associated with pancreaticoduodenectomy. [4] [5] [6] [7] [8] Tempering any reluctance to undertake pancreaticoduodenectomy without confirmation of cancer is the knowledge that timely pancreaticoduodenectomy provides the only opportunity for cure of pancreatic adenocarcinoma and the best opportunity for prolonged survival. On occasion, we have noted that operative findings or final examination by Pathology did not justify the pancreaticoduodenectomy undertaken. In undertaking this study, we have identified the potential to decrease the number of unnecessary pancreatic resections undertaken at our institution. Specifically, we have identified the following avenues to improve the care delivered to patients with undocumented pancreatic neoplasia: (i) re-review of all biopsy/cytology specimens, (ii) cautious approach to patients with a history of pancreatitis or known precipitating causing of pancreatits, and (iii) careful interpretation of radiographical imaging.
Central to any evaluation regarding patient selection for a given intervention is the safety of that intervention. In other words, the risk/benefit analysis for each patient, particularly those without confirmation of disease, must take into account operative mortal-ity as well as expected post-operative morbidity. With regard to pancreatic pathology and specifically undertaking pancreaticoduodencetomy, increasing evidence suggests that morbidity and mortality can be minimized if the resection is undertaken by high volume surgeons in high volume centres. [9] [10] [11] [12] For example, the mortality rate for patients undergoing pancreaticoduodenectomy at low volume centres and in specialized centers of excellence are 12% and 2%, respectively. 2, 13 Therefore, stratification of care to specialized centres may be particularly appropriate for patients with suspected solid and cystic pancreatic neoplasms given the more favourable risk/benefit profile associated with care at these institutions.
The management of cystic lesions of the pancreas has evolved along with our understanding of their natural history as well as improved diagnostic imaging and procedures. The International Association of Pancreatology reviewed the available literature regarding intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) and defined resection criteria.
14 In short, all MCNs and main duct IPMNs should be resected, whereas side branch IPMN may be observed if <3 cm and without suggestive radiographical features. For the purposes of this study, we considered all patients with IPMN, irrespective of ductal origin, to have undergone resection out of necessity given the very recent clarification of the natural history of this disease and study time-frame during which patients received treatment. Serous cystadenomas (SCA) are another commonly encountered neoplastic cyst but are, with few exceptions, low risk for malignancy. There have been 10 cases of malignant SCA reported in the English literature and the risk of malignancy has been estimated to be <3%. 15, 16 Recently growth rates for SCA have been identified as being important in the decision process to resect; tumours less than 4 cm grow 0.12 cm/year whereas those >4 cm grow 2 cm/ year. 17 The implications of differential growth rates upon malignant transformation, if any, remain unknown but nonetheless contribute to management recommendations. Patients with SCA greater than 4 cm, particularly those associated with symptoms, are recommended to undergo resection, assuming appropriate fitness for operative intervention. 17, 18 For the purposes of this study, we considered all patients with SCA greater than 4 cm to have undergone resection out of necessity irrespective of associated symptoms, although four out of the five patients in the present study with SCA greater than 4 cm were symptomatic (data no shown).
Implicit in the management of various cystic pancreatic lesions is the ability to accurately diagnose them. Indeed, resection criteria for SCA include the inability to distinguish them from MCN. This distinction can be particularly problematic for oligocystic and macrocystic variants of SCA when CT alone is utilized for diagnosis. However, EUS with FNA may increase our ability to accurately stratify patients. For example, cyst CEA levels have been shown to strongly correlate with malignant potential. 19, 20 Newer proprietary DNA platforms have also been developed and assign probability of malignancy based upon measured genetic mutations. 21, 22 We have tried proprietary DNA platforms without much success to date. In our study, nearly 70% of patients with cystic masses undergoing unnecessary procedures did so because of false-positive preoperative biopsies or imaging misinterpretations. Our data therefore support those conclusions of Hartwig et al. in their recent review of the literature regarding the need for a preoperative tissue diagnosis for tumours of the pancreas; it is generally not advisable. 23 Solid pancreatic lesions can be problematic. The overwhelming majority of solid masses in the pancreas will be malignant, particularly when associated with symptoms, making the uncommon benign solid mass difficult to identify preoperatively. Even although EUS-guided FNA has become standard practice in some centres, negative or equivocal results are not particularly useful, baring rare diagnoses such as biliary hamartoma. Pancreatic biopsies are subject to sampling error given the intense peritumoral desmoplastic reaction associated with malignancies and therefore are far less accurate than when applied to cystic pancreatic lesions. Although serum CA 19-9 may be a reliable marker for cancer recurrence after resection, it is an unreliable diagnostic test as elevations are known to occur with both malignant and benign pathology and elevations may not occur with malignant disease, particularly early disease. 24 We have identified that the majority of patients with non-neoplastic solid masses undergoing pancreaticoduodenectomies for suspected malignancies will ultimately prove to have pancreatitis. Furthermore, pancreatic malignancies are not infrequently associated with pancreatitis, either causally or as a result of long-standing chronic pancreatitis. We have not found utility in the use of other imaging modalities such as positron emission tomography (PET) to differentiate benign and malignant pancreatic lesions, although a standardized uptake value (SUV) cut-off of 2.0 has been suggested to aid in the differentiation of chronic pancreatitis from pancreatic cancer. 25 We have found a false-negative rate of 20% even in large locally advanced pancreatic cancers and are very skeptical of negative PET scans (unpublished data). Others have noted a slightly higher SUV for pancreatic cancer than chronic pancreatitis, but the falsepositive results are generally prohibitive for use in any definitive manner. 26 However, we have identified 11 patients with a final diagnosis of pancreatitis, including eight patients with solid masses, for whom histories and imaging were felt to be sufficient for a correct preoperative diagnosis. These patients may warrant aggressive preoperative diagnostics and a short, definable observation period with repeat imaging rather than dismissal for the reasons outlined above.
In undertaking this study, we chose to focus on the diagnostic and clinical data available to the operating surgeon at the time the procedure was undertaken, and reserved categorization of patients as needing more workup to the circumstance that the addition of a specific test was very likely to yield the correct diagnosis. It is important to note that this study spans over a decade. Some diagnostic measures are now more readily available, such as EUS with FNA. Notably, it seems that the majority of patients undergoing unnecessary pancreaticoduodenectomies did so prior to our more frequent use of EUS, although most patients had solid, not cystic, lesions. The study methodology also has several important inherent biases. Our methodology presumed that all pancreatectomies without neoplasia were unnecessary; we defined them as such. It is, however, likely that a number of the patients in this study required an operation (possibly a pancreaticoduodenectomy) for symptom relief alone and therefore we may have inflated the number of patients undergoing unnecessary resections. In addition, there is the error inherent in any process of peer-review. In particular, final diagnoses by Pathology were inevitably made known during the review process, which may have affected outcome.
In reviewing patients undergoing unnecessary pancreaticoduodenectomies based upon final diagnoses by Pathology, we have stratified patients by evaluation of pertinent clinical and radiographical data in the hope of improving the quality of care delivered to patients at our institution and to identify the mimes of malignancy. With vigilant review of biopsy specimens, implementation and interpretation of evolving imaging diagnostics, as well as a cautious approach to patients with strong suspicion for pancreatitis, a large percentage of unnecessary pancreaticoduodenectomies can be avoided. Even with the implementation of recommendations based upon the findings of this study, we recognize that 'due diligence' will, nevertheless result in a number of patients undergoing unnecessary resections, albeit at reduced rates. In particular, we have identified symptomatic patients presenting with a solid pancreatic mass as problematic, particularly given that this cohort of patients will contain very few mimes of malignancy and the majority of the mimes will be unrecognized until final examination by Pathology.
